Əsas səhifə

Çap

Əks əlaqə

İnfo
Intravaginal estriol and the endometrium

Mündəricat

Intravaginal estriol and the endometrium

Sübutlu məlumatların xülasələri
03.07.2018 • Sonuncu dəyişiklik 03.07.2018
Editors

Single daily intravaginal estriol (0.5 mg) in postmenopausal women appears not to increase the risk of endometrial proliferation or hyperplasia.

A systematic review including 12 studies with a total of 214 subjects was abstracted in DARE. The participants used 0.5 mg of estriol cream or suppository once a day for two or three weeks, followed by a gradual reduction to 0.5 mg twice per week. All 337 post-baseline endometrial biopsies were classified as atrophic by the authors of the primary studies. These included 61 biopsies at 6 months after the commencement of treatment and 58 at one year.

Comment: The quality of evidence is downgraded by imprecise results (few patients with long-term follow-up).

Ədəbiyyat

  1. Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 1995 Sep;62(1):101-6.